Abstract: ［Abstract］ Objective Brother of regulator of imprinted sites （BORIS） was a DNA-binding protein that was normally expressed in the testes and associated with some kinds of tumor malignancy. The aims of the present study was aimed to investigate BORIS expression in gastric cancer （GC） and found out the prognostic value of this proteins. Methods Using immunohistochemical staining， BORIS expression was studied to assess potential correlation between BORIS expression in GC following radical surgery with clinicalpathological parameters and overall survival in this study. Survival analysis was performed and compared using Kaplan?Meier curves， Life?table， log?rank test， and Cox regression analysis. Results BORIS expression was significantly higher in GC tissues than in normal adjacent tissues. In 63.1% （41 of 65 cases） BORIS was observed in stomach tumors. BORIS expression was associated with tumor invasion， lymph node metastasis and advanced TNM stage. Furthermore， those patients with BORIS positive had worse survival outcome compared with the ones with BORIS negative （5?year survival rate： 22.0% vs 49.8%， P=0.009）. Univariate Cox regression analysis revealed that BORIS expression was a prognostic parameter in out study. Conclusion BORIS was a promising indicators for predicting clinicopathological features and prognosis in GC cases.

Key words: prognosis, BORIS, gastric cancer, immunohistochemistry

摘要： ［摘要］ 目的 本研究旨在探讨BORIS在胃癌中的表达水平及其预后价值。方法 采用免疫组织化学的方法探讨BORIS蛋白的表达水平与接受胃癌根治术患者的临床病理特点及总体生存预后的关系，并采用Kaplan-Meier法、Life-table法、log-rank及Cox回归分析进行生存分析。结果 胃癌组织中BORIS免疫组化阳性率为63.1%（41/65），明显高于癌旁正常胃组织。BORIS的表达与肿瘤浸润、淋巴转移和进展期的TNM分期显著相关。BORIS阳性的胃癌患者总体预后显著差于BORIS阴性者（5年总体生存率分别为22.0%和49.8%，P=0.009）。单因素Cox回归分析结果显示BORIS表达是影响本组胃癌患者生存预后的因素。结论 BORIS可能作为预测胃癌临床病理特点及生存预后的生物标记物。

关键词: 生存预后, BORIS, 免疫组织化学, 胃癌